Paradigm Biopharmaceuticals Ltd.ASX: PAR

Phase 3 Protocol Submission to US FDA

Oct 31, 2024 at 1:41 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment